Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
BioPharmaceutical Asia Pacific South Korea

INTERVIEW: Korea Initiative Aims To Create Global Clinical Trial Hub

This article was originally published in PharmAsia News

Executive Summary

In a recent interview with PharmAsia News, the head of the Korea Clinical Trial Global Initiative stressed the importance of continued government support in boosting the country’s competitiveness in clinical trials, amid narrowing gaps with its Asian rivals. He also talked about why the initiative is focusing on attracting early phase work from foreign firms and what South Korea needs to do to maintain its edge.

Table

View full table

Topics

Tags:
BioPharmaceutical Asia Pacific South Korea
Latest Headlines

Are Jubilant Pharmova’s US Plant Closure, FDA Observations At Canada Unit A Concern?

X4 Gets First Approval In Ultra-Rare Disorder, Needs Time To Build A Market

Ono Buys Deciphera, Gaining A Commercial Cancer Drug And Infrastructure

AstraZeneca And Daiichi Get Low

See All
UsernamePublicRestriction

Register

SC089592

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By